Adverse Effects of Intravesical OnabotulinumtoxinA Injection in Patients with Idiopathic Overactive Bladder or Neurogenic Detrusor Overactivity: A Systematic Review and Meta-Analysis of Randomized Controlled Studies
Toxins · 2024
DOI: 10.3390/toxins16080343 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Toxins, 2024. Verfasst von Ping-Hsuan Yu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, En Chu Kong Hospital, College of Medicine, National Taiwan University, New Taipei City 237414, Taiwan. Hauptthemen laut MEDLINE: Botulinum Toxins, Type A, Urinary Bladder, Neurogenic, Urinary Bladder, Overactive. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Despite the efficacy of onabotulinumtoxinA, its safety profile remains a concern. This meta-analysis reviewed the major adverse events (AEs) associated with intravesical onabotulinumtoxinA treatment in patients with neurogenic detrusor overactivity (NDO) and idiopathic overactive bladder (iOAB). Randomized controlled trials (RCTs) conducted between January 2000 and December 2022 were searched for adult patients administered different onabotulinumtoxinA dosages or onabotulinumtoxinA vs. placebo. Quality assessment was performed using the Cochrane Collaboration tool, and statistical analysis was performed using Review Manager version 5.3. A total of 26 RCTs were included in the analysis, including 8 on NDO and 18 on iOAB. OnabotulinumtoxinA vs. placebo significantly increased the urinary tract infection (UTI) incidence in patients with NDO (relative risk, or RR, 1.54) and iOAB (RR, 2.53). No difference in the RR with different onabotulinumtoxinA dosages was noted. Urinary retention was frequent with onabotulinumtoxinA use in the NDO (RR, 6.56) and iOAB (RR, 7.32) groups. Similar observations were made regarding the risks of de novo clean intermittent catheterization (CIC). The risk of voiding difficulty increased with onabotulinumtoxinA use in patients with iOAB. Systemic AEs of onabotulinumtoxinA, including muscle weakness (RR, 2.79) and nausea (RR, 3.15), were noted in patients with NDO; most systemic AEs had a low incidence and were sporadic.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, En Chu Kong Hospital, College of Medicine, National Taiwan University, New Taipei City 237414, Taiwan.
- Department of Urology, Taipei Veterans General Hospital, Taipei 112201, Taiwan.
- Department of Urology, College of Medicine, National Yang Ming Chiao Tung University, Taipei 112304, Taiwan.
- Shu-Tien Urological Science Research Center, National Yang Ming Chiao Tung University, Taipei 112304, Taiwan.
- Department of Biomedical Engineering, Chung Yuan Christian University, Taoyuan 320314, Taiwan.
ORCID-Profile: Ping-Hsuan Yu, Chung-Cheng Wang
Zitieren
APA
Yu, P. H., & Wang, C. C. (2024). Adverse Effects of Intravesical OnabotulinumtoxinA Injection in Patients with Idiopathic Overactive Bladder or Neurogenic Detrusor Overactivity: A Systematic Review and Meta-Analysis of Randomized Controlled Studies. Toxins. https://doi.org/10.3390/toxins16080343
Vancouver
Yu PH, Wang CC. Adverse Effects of Intravesical OnabotulinumtoxinA Injection in Patients with Idiopathic Overactive Bladder or Neurogenic Detrusor Overactivity: A Systematic Review and Meta-Analysis of Randomized Controlled Studies. Toxins. 2024. doi:10.3390/toxins16080343
BibTeX
@article{Yu2024,
author = {Yu, Ping-Hsuan and Wang, Chung-Cheng},
title = {Adverse Effects of Intravesical OnabotulinumtoxinA Injection in Patients with Idiopathic Overactive Bladder or Neurogenic Detrusor Overactivity: A Systematic Review and Meta-Analysis of Randomized Controlled Studies},
journal = {Toxins},
year = {2024},
doi = {10.3390/toxins16080343}
}
EUVIMED